Cointime

Retinal Degeneration Fund

investment firm

About

Retinal Degeneration Fund makes mission-related investments in therapeutic companies with projects nearing clinical testing.

Highlights

Investments
7
Lead Investments
1
Exits
1
Employee Profiles
2

Details

Industries
Business Development,Financial Services,Therapeutics
Founded date
Jan 1, 2018
Operating Status
Active
Also Known As
RD Fund
Investor Type
CVC

Retinal Degeneration Fund helps in accelerating life-changing outcomes for people with retinal degenerations through direct mission-related investments in therapeutic companies.

The Retinal Degeneration Fund (RD Fund) is a not-for-profit subsidiary of the Foundation Fighting Blindness launched in 2018.

Investments

Number of Investments
Number of Lead Investments
7
1
Retinal Degeneration Fund has made 7 investments. Their most recent investment was on Sep 14, 2022, when SparingVision raised €75M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 14, 2022 SparingVision
Series B €75M Biotechnology —
Jun 15, 2022 Nacuity Pharmaceuticals
Series B $16.50M Health Care —
Jan 5, 2022 SalioGen Therapeutics
Series B $115M Biotechnology —
Sep 22, 2021 Opus Genetics
Seed $19M Health Care Yes
May 18, 2021 Vedere Bio ll
Series A $77M Biotechnology —
Show More

Employee Profiles

Number of Employee Profiles
2
Retinal Degeneration Fund has 2 current employee profiles, including Executive Benjamin Yerxa
Benjamin Yerxa
Executive
Rusty Kelley
Executive

Exits

Retinal Degeneration Fund has had 1 exits. Retinal Degeneration Fund most notable exits include Vedere Bio ll

Date Company Name Exit Type Industry
Oct 29, 2020 Vedere Bio ll M&A Biotechnology Detail
Cointime
Content
Company